Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Merchant, this is a lot of cash, aNd a good % of T/O, perhaps just on paper but it’s turned ODX from expected profit to unexpected loss. Agree with prioritisation, but to me (and this is my personal opinion) the past Decision on products pulled into ODX’s portfolio wasn’t the best one. I saw the 7.7 mainly as cost of reversal.
Agree PR is the weak point. But they aren't really being given much of a chance at the moment to turn it around. Let's see how the presentation goes.
The £7.7m impairment is good management not bad management. Why do you want them diverting resources to a small business that is costing us money and a long way off making returns when we now have covid? Don't you think resources are better used on Covid tests? It's a non cash item of sunk costs, shutting down a business that is losing money.
Agree merchant - no need to be “too” greedy here, but I will say.. Between poor PR, cancellation of product lines that aren’t even that old, and finally the exceptional charges of GBP7.7 million = Very unexceptional management!!!! IMHO
Come on Sam your starting to sound desperate now with all this posting.
Mr Investment...
Firstly i think any of us will be happy with £500m.
The top end valuation needs everything to click into place including the antigen tests. The antigen tests are of higher worth, so the £1 per test would be more like £3 average with the antigen tests running at a product sensible mix.
These test will be needed for longer than you think. If it takes 12-18 months to control the virus testing will go on for much longer. Even if it is considered that the virus is disappearing they will still continue to test to prove this, because just one case could cause a new spread.
More importantly, regarding the valuation, longevity of these revenues is not necessarily the be all and end all. It is the manufacturing capacity that has the value, so in building the manufacturing capacity it is down to ODX to replace that capacity with other tests when covid does start to decline. As mentioned in the presentation they expect the manufacturing capacity to be continued post covid with other tests. Tests that may even be more profitable. Cd4 will increase and they are working on new tests. We will be at the centre of the UK diagnostics industry. They can offer manufacturing capacity up to any company that have any test. So i dont see covid as a limiting factor in relation to utilisation of manufacturing capacity.
But aside from that, the short term cash flow generation will be so significant, its also about what they do with that cash. That cash wont disappear. They could pay a dividend, do a share buy back, or invest it in something else. This is why the valuation will be maintained and it isnt just a one time pay day.
Also the £970m valuation is on a modest income multiplier to take into account the uncertainty.
£30-£40m profit will be easy at really poor capacity utilisation, and £100m would only be 2 and a bit times income multiplier which is a very low income multiplier.
No it's not for us poor investors, its for the sake of the little pooches, ****atoes and bunny rabbits.
Paid to post.. sitting somewhere in Eastern Europe or possibly Africa.
The OO would have brought this to the attention of short sweat shops, now they will attack any sign of weakness such as no annoucing million £ orders every RNS
Sam_Pullcox - I think you're the one that can't get it. sell up and go. No one here will miss you.
Sam_Pullcox with respect your profile has been around for 11 days and you have posted 80 times on ODX and only ODX. So we get that you do not like the company we just don't get why you are investing 'your energy' posting?
Further elaboration on this part as well:
"The only have to sell 200k RTC tsts a week and 46k Elisa tests to get to £200m MCAP. Achieve maximum capacity and deliver growth in existing business high end valuation of £970m"
Prospects now are many times better than they were in April. Fact.
Capacity 4x greater than expectation
Instead of 1 UK RTC test in development and 1 Mologic Elisa test we have 5 tests including antigen, and RTC out of development into design freeze.
Duble D - Define the market. What does the market know? The market knows how to rip people off. The market knows how to change peoples beliefs. And the market is doing a very good job of it.
Meanwhile ODX are building a business with high growth potential and i will wait with my shares and add more when i can.
For Antibody tests, prospects are now a lot better.
How many of you have read about a person being infected a 2nd or 3rd time? Not many.
Antibodies do protect. If its only for months then great. Odx will have to produce more to keep up with demand.
If you cannot see the value in ODX, sell up and go.
When the 'home test' antibody is on the market, we will all be fighting to get one. ODX will make millions.
Sometimes, you have to take 2 steps backwards to move a step forward. That is what ODX have done.
PR can improve and will improve i'm sure but the fundamentals are astounding here.
If you're not happy to hold, f off. Stop with the negativity. We've had enough of it.
MB, keep up the great work!
And what were people saying about HEMO as it plunged from 15p to 5p.. ? No hope company.. hype is over .. etc etc.
Sam - I havn't been wrong. I am not calling this as a trader trying to benefit from every up and down. I am calling this as a business prospect and potential for growth. That has always been clear from my posts. I can't account for the market reactions, but i know that long term i am right.
The share price being down is not just, it's a reflection of AIM and how people react and not a reflection of the business.
I don't care if people buy or sell they can do what they want and i will never encourage anyone to do either. I only say it how i see it from a business point of view.
The point i am making is the gap between value and the actual share price is increased dramatically, which stands good for a reversal.
The market sp is a snapshot of sentiment in time. It can change on a whim and go up or down quickly , research what you believe to be fundamentals before deciding.
Merchant - so you think you know better than the markets??? Jeez.
I'd suggest that just for a bit of fun that everyone reads Sam's posts for the last 11 days. I think he sold this morning and now wishes he hadn't....comments please!
Correct Pilgrim. It's the early adopters with inferior products rushed to market that will suffer.
Once RTC test is on the market there will be no superior product to trump it for demand. They have taken the time to get the product right so that it will be of the highest quality.
Mologic tests are of high enough quality at competitive prices to attract enough demand to capacity. Most people have no idea what these tests offer compared to others on the market. Those that have done their research will know why they will be in high demand. You have to look at cost, accessibility, high volume throughput and well as specificity and sensitivity. The Mologic offerings are highly competitive on all accounts. Then you have to look at Omega's distribution network. PR may not be their forte, but distribution of product to market is and that's where the money is.
We have a unique position where we have lab and lateral flow antigen and antibody tests. They will be able to adapt their product mix to meet demand and maximise capacity.
AVCT valued at £300m just on Antigen tests alone that have a lower chance of success than ours.
Merchant makes a lot of valid points, it is up to the individual how much weight to attach. Anyone making a trading decision based on his or anyone else's opinion is being stupid. Make your own decision after doing your own research, and ignore posts that just malice.
He's the share police
sam_pull****
who claims that the market agrees with them?
Sam Pullcox...the hype may be dying with small minded traders but Covid worldwide hasn't even peaked yet. You really should take off your blinkers and understand ODX will be selling these tests worldwide for years to come..this isn't a little 6 month bubble and then everything blows over like most PI's seem to believe...they going flat out to get approvals, the tech is fantastic, the sp has suffered as short term traders are now out...thanks god for that.
Why no mention of pet or alien antibody testing?